CrystalGenomics "Complex Drugs Aselex and Tramadol Patented in Mexico"

Expansion of Indications for Acute and Chronic Pain

CrystalGenomics announced on the 25th that it has obtained a patent in Mexico for 'Aselex' (active ingredient: Polmacoxib) and the tramadol combination drug 'CG-650,' both under development as combination drugs.

CrystalGenomics CI. [Image provided by CrystalGenomics]

The patent is titled "Pharmaceutical composition for acute and chronic pain treatment containing Polmacoxib and Tramadol." This formulation patent refers to a patent on the buffer agents additionally used to stabilize the substance (drug). Using these more stable raw materials of Aselex and tramadol, it enables the development of various formulations, including oral formulations that can improve patient compliance.

Only after securing the formulation patent can the product enter the market following approval from each country's pharmaceutical regulatory authorities. The patent is valid until June 8, 2038, during which time other companies are fundamentally prevented from manufacturing the product using the same method.

Combination drugs are pharmaceuticals that improve the shortcomings of original drugs by using various technologies such as formulation changes and salt changes. The company explained that these drugs are safer, more effective, and offer greater dosing convenience than existing products, thereby securing competitiveness.

A CrystalGenomics representative stated, "Through the patent in Mexico, the largest market in Latin America, we expect to extend the exclusive sales period and expand the market by advancing the development of the Aselex combination drug using lifecycle management strategies."

This content was produced with the assistance of AI translation services.